Design Therapeutics (DSGN) Current Assets (2020 - 2026)

Design Therapeutics has reported Current Assets for 7 years, with the latest figure at $212.0 million in Q2 2026.

• Current Assets for Q2 2026 came in at $212.0 million, down 3.54% year-over-year; the trailing twelve-month figure through Jun 2026 was $212.0 million (down 3.54% YoY), and the FY2025 annual result was $223.8 million, down 9.78% from the prior year.
• Current Assets declined to $212.0 million in Q2 2026, from $227.0 million in the prior quarter.
• Over five years, Current Assets peaked at $373.9 million in Q1 2022 and troughed at $209.0 million in Q3 2025.
• A 5-year average of $277.4 million and a median of $269.4 million in 2024 frame the typical range for Current Assets.
• The widest annual swing landed in 2025, when Current Assets decreased 18.74%; it then fell 2.82% in 2026.
• A 5-year view of Current Assets shows it stood at $335.1 million in 2022, then fell by 15.08% to $284.6 million in 2023, then retreated by 12.84% to $248.0 million in 2024, then dropped by 9.78% to $223.8 million in 2025, then declined by 5.26% to $212.0 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $212.0 million in Q2 2026, $227.0 million in Q1 2026, and $223.8 million in Q4 2025.